ALMRY 財務： Almirall SA AI 分析

首頁

股票

ALMRY

財務狀況

ALMRY 財務

Almirall SA

$14.28

收盤價：Mar 26, 16:00:00 GMT-4

$14.28

盤後：Mar 26, 20:00:00 GMT-4

概觀預測收益股利財務狀況

收入

資產負債表

現金流量

年度

每季

ALMRY 收入

財務數據以百萬美元計。會計年度為二月至一月。

Breakdown	TTM	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
營收	1,652	1,108	985	894	863	827
營收年增率 (YoY)	13%	12%	10%	4%	4%	2%
營收成本	425	236	218	212	181	172
毛利	1,227	871	767	682	681	654
銷售、一般及管理費用	515	339	291	250	253	222
研發	162	96	79	66	64	41
營業費用	1,098	798	718	641	626	551
其他非營業收入 (費用)	-9	-8	-7	-7	-5	-7
稅前淨利	131	74	26	-17	31	-9
所得稅費用	50	28	16	21	26	31
淨利	80	46	10	-38	4	-40
淨利成長	789%	360%	-126%	-1,050%	-110%	-154%
稀釋後流通股數	214.58	213.99	212.74	200.64	187.94	184.4
股數年變動 (YoY)	-1%	1%	6%	7%	2%	1%
每股盈餘 (稀釋)	0.37	0.21	0.04	-0.19	0.02	-0.22
每股盈餘成長率	686%	352%	-125%	-941%	-110%	-155%
自由現金流	37	37	0	-65	38	162
每股自由現金流	--	--	--	--	--	--
毛利率	74.27%	78.61%	77.86%	76.28%	78.91%	79.08%
營業利益率	7.8%	6.58%	4.97%	4.47%	6.25%	12.33%
淨利率	4.84%	4.15%	1.01%	-4.25%	0.46%	-4.83%
自由現金流利潤率	2.23%	3.33%	0%	-7.27%	4.4%	19.58%
EBITDA	342	224	188	164	174	221
EBITDA 利潤率	20.7%	20.21%	19.08%	18.34%	20.16%	26.72%
EBITDA 中的折舊與攤銷	213	151	139	124	120	119
EBIT	129	73	49	40	54	102
EBIT 利潤率	7.8%	6.58%	4.97%	4.47%	6.25%	12.33%
有效稅率	38.16%	37.83%	61.53%	-123.52%	83.87%	-344.44%

Follow-Up Questions

Almirall SA 的關鍵財務報表是什麼？



根據最新的財務報表（Form-10K），Almirall SA 的總資產為 $2,337，淨isProfitable}為 $46

ALMRY 的關鍵財務比率是什麼？



Almirall SA 的流動比率為 2.74，淨利潤率為 4.15，每股銷售為 $5.17。

Almirall SA 的收入按細分市場或地理位置如何劃分？



Almirall SA 最大收入來源為 Commercial - Own Network (Europe)，在最近的收益報告中收入為 808,381,000。就地區而言，Spain 是 Almirall SA 的主要市場，收入為 305,232,000。

Almirall SA 是否盈利？



是的，根據最新的財務報表，Almirall SA 的淨利潤為 $46

Almirall SA 有負債嗎？



是的，Almirall SA 的負債為 850

Almirall SA 的流通股有多少？



Almirall SA 的總流通股為 214.78

關鍵數據

前收市價

$14.28

開盤價

$15.8

當日範圍

$14.28 - $15.8

52週區間

$11.5 - $15.8

交易量

100

平均成交量

股息收益率

每股盈餘 (TTM)

0.25

市值

$3.0B

什麼是 Almirall SA？

Almirall SA is a global biopharmaceutical company, which is focused on skin health. The company is headquartered in Barcelona, Barcelona and currently employs 2,026 full-time employees. The company went IPO on 2007-04-19. The firm focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The firm's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The firm operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.

功能特性

資源